Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 24, 2026

Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV

View original at finance.yahoo.com
Better Health Care ETF: Fidelity's FHLC vs…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FHLC provides broader market-cap exposure including mid- and small-cap stocks, capturing companies that XLV skips by tracking only S&P 500 healthcare components

    60% confidence
  • XLV generated a growth of $1,284 from a $1,000 investment over five years on a total return basis, outperforming FHLC's $1,231 over the same period despite lower 1-year return

    60% confidence
  • FHLC has a trailing-12-month dividend of $1.01 per share, and its broader MSCI-based index captures small- and mid-cap companies that XLV skips

    60% confidence
  • XLV has paid $2.51 per share in distributions over the trailing 12 months, with a dividend yield of 1.7% versus FHLC's 1.4%

    60% confidence
  • XLV offers superior liquidity and a higher trailing-12-month dividend yield compared to FHLC, making it more suitable for income-seeking investors

    60% confidence

Data points we hold from this source

AbbVie Inc. · portfolio weight in xlv7.09 percent
AbbVie Inc. · portfolio weight in fhlc6.06 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,351 source documents archived
Query this data → isubstrate.com